MPS1

MPS1 Products

  • All (7)
  • MPS1 Inhibitors (7)
  • New MPS1 Products
Catalog No. Product Name Information Product Use Citations Product Validations
S2731 AZ 3146 AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit.
Research Square, 2024, 10.21203/rs.3.rs-2161438/v1
Nat Commun, 2023, 14(1):6505
Cell Prolif, 2023, 56(4):e13384
S8215 BAY 1217389 BAY 1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1) with IC50 values below 10 nmol/L while showing an excellent selectivity profile.
Nat Commun, 2023, 10.1038/s41467-023-43274-3
Dev Cell, 2023, 58(3):192-210.e11
bioRxiv, 2023, 2023.04.02.535275
S7488 MPI-0479605 MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases.
Nature, 2022, 604(7904):146-151
J Ovarian Res, 2021, 14(1):128
Front Pharmacol, 2020, 30;11:543
S8214 Empesertib (BAY1161909) Empesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of <1 nM. Empesertib has potential antineoplastic activity.
Sci Adv, 2023, 9(3):eadd6982
S8911 BOS172722 BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM.
E1428New Mps1-IN-6 (Compound 9) Mps1-IN-6 (Compound 9) is a potent Mps1 inhibitor with IC50 of 6.4 nM. It also exhibits antiproliferative and anti-tumor activity in breast cancer cells.
S6768 CC-671 CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.
S2731 AZ 3146 AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM, contributes to recruitment of CENP-E (kinesin-related motor protein), less potent to FAK, JNK1, JNK2, and Kit.
Research Square, 2024, 10.21203/rs.3.rs-2161438/v1
Nat Commun, 2023, 14(1):6505
Cell Prolif, 2023, 56(4):e13384
S8215 BAY 1217389 BAY 1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1) with IC50 values below 10 nmol/L while showing an excellent selectivity profile.
Nat Commun, 2023, 10.1038/s41467-023-43274-3
Dev Cell, 2023, 58(3):192-210.e11
bioRxiv, 2023, 2023.04.02.535275
S7488 MPI-0479605 MPI-0479605 is an ATP competitive and selective inhibitor of mitotic kinase Mps1 with IC50 of 1.8 nM, >40-fold selectivity over other kinases.
Nature, 2022, 604(7904):146-151
J Ovarian Res, 2021, 14(1):128
Front Pharmacol, 2020, 30;11:543
S8214 Empesertib (BAY1161909) Empesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of <1 nM. Empesertib has potential antineoplastic activity.
Sci Adv, 2023, 9(3):eadd6982
S8911 BOS172722 BOS172722 is a monopolar spindle 1 (MPS1) checkpoint inhibitor with IC50 of 11 nM, Ki of 0.11 nM.
E1428New Mps1-IN-6 (Compound 9) Mps1-IN-6 (Compound 9) is a potent Mps1 inhibitor with IC50 of 6.4 nM. It also exhibits antiproliferative and anti-tumor activity in breast cancer cells.
S6768 CC-671 CC-671 is a selectively dual inhibitor of TTK (human protein kinase monopolar spindle 1 [hMps1]) and CDC like kinase 2 (CLK2) with IC50s of 5 nM and 3 nM for TTK and CLK2, respectively.
E1428New Mps1-IN-6 (Compound 9) Mps1-IN-6 (Compound 9) is a potent Mps1 inhibitor with IC50 of 6.4 nM. It also exhibits antiproliferative and anti-tumor activity in breast cancer cells.

Choose Selective MPS1 Inhibitors

Tags: MPS1 inhibitor|MPS1 agonist|MPS1 activator|MPS1 inducer|MPS1 antagonist|MPS1 signaling pathway|MPS1 assay kit